Dow, Cambrex complete operational facility for drug solubility enhancement

12:23 PM, 30th October 2013

HORGEN, SWITZERLAND/KARLSKOGA, SWEDEN: The Dow Chemical Company and Cambrex have completed the new operational facility for Dow’s hydroxypropyl methylcellulose acetate succinate (HPMCAS) for drug solubility enhancement. The Cambrex Karlskoga facility expansion began in early 2013. Starting early 2014, Dow will be able to commercially supply solubility enabling excipients.

“We are proud to have completed this carefully executed expansion in such a short amount of time. This has been a great collaboration with both the Dow and Cambrex teams focused on meeting project goals. This partnership between Dow and Cambrex further demonstrates Cambrex's commitment to finding solutions that allow our clients to meet a market need in a timely manner,” said Bjarne Sandberg, Managing Director, Cambrex Karlskoga.

0 Comments

Your Comments (Up to 2000 characters)

Please respect our community and the integrity of its participants. WOC reserves the right to moderate and approve your comment.

Submit

MUTTENZ, SWITZERLAND: Clariant, a world leader in specialty chemicals, plans to sell its Leather Services business to Stahl Holdings BV, majority-owne ...

Asahi Kasei completes construction of new research complex in Japan

TOKYO, JAPAN: Asahi Kasei Pharma has completed the construction of a new research complex in its pharmaceuticals research centre in Shizuoka, Japan, a ...

Evonik opens organic specialty surfactants facility in Shanghai, China

ESSEN, GERMANY: Evonik Industries has opened a new production facility for organic specialty surfactants in the Shanghai Chemical Industry Park (SCIP) ...

DuPont expands China R&D centre

SHANGHAI, CHINA: DuPont opened the second phase of its China Research and Development Centre. With this expansion, the DuPont China R&D Centre add ...

EuroChem starts phosphate rock drilling operations in Kazakhstan